TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12578874

Group type: EXPERIMENTAL
Intervention: HF-nlEF patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Age- and blood pressure-matched controls
Number of subjects: 10
Study: 10656116

Group type: EXPERIMENTAL
Intervention: Modified Anda-TB enzyme immunoassay test
Number of subjects: 0
Study: 8777677

Group type: EXPERIMENTAL
Intervention: PN+selenium (3 micrograms/kg/day of selenious acid)
Number of subjects: 38

Group type: COMPARATOR
Intervention: PN-selenium (non-supplemented)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PN+selenium
Number of subjects: 38

Group type: COMPARATOR
Intervention: Term breastfed infants
Number of subjects: 38
Study: 2050539

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 1500 mg daily
Number of subjects: 298

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 298
Study: 6670591

Group type: EXPERIMENTAL
Intervention: Iohexol (10 to 15 ml, 180 mg I/ml)
Number of subjects: 30
Study: 30762691

Group type: EXPERIMENTAL
Intervention: Primary tumor resection or amputation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Primary tumor resection
Number of subjects: 200

Group type: COMPARATOR
Intervention: No primary tumor resection
Number of subjects: 200
Study: 30249462

Group type: EXPERIMENTAL
Intervention: TAVR (Transcatheter Aortic Valve Replacement)
Number of subjects: 797

Group type: COMPARATOR
Intervention: SAVR (Surgical Aortic Valve Replacement)
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 797

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 797
Study: 26758251

Group type: EXPERIMENTAL
Intervention: DE + allergen (DEA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FAA
Number of subjects: 12

Group type: COMPARATOR
Intervention: Filtered air + saline (FAS)
Number of subjects: 12
Study: 24652053

Group type: EXPERIMENTAL
Intervention: Dietary intervention + placebo (DIP)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dietary intervention + supplementation of omega 3 (DIS3)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dietary intervention + placebo + physical activity (DIPE)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dietary intervention + physical activity + supplementation of omega 3 (DIS3PE)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 70
Study: 23299064

Group type: EXPERIMENTAL
Intervention: Cefuroxime 250 mg twice daily for 10 days (n=57)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Co-amoxiclav 500/125 mg three times daily for 10 days (n=42)
Number of subjects: 99
Study: 20410427

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound and MR angiography measurements (renal length, total and cortical volumes, resistive index)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Renal length and cortical volume weighted by resistive index
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Threshold of renal length-resistive index product less than 7 cm
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Threshold value of 52 mL/m(2) for cortical renal volume-resistive index product
Number of subjects: 51
Study: 17234558

Group type: EXPERIMENTAL
Intervention: MMX mesalamine 2.4 g/day given twice daily
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: MMX mesalamine 4.8 g/day given once daily
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280
Study: 15870503

Group type: EXPERIMENTAL
Intervention: 20 mg pantoprazole
Number of subjects: 529

Group type: COMPARATOR
Intervention: 20 mg esomeprazole
Number of subjects: 529
Study: 12140806

Group type: EXPERIMENTAL
Intervention: Multidisciplinary care (MDC), n = 51
Number of subjects: 98

Group type: COMPARATOR
Intervention: Routine care (RC), n = 47
Number of subjects: 98
Study: 10676544

Group type: EXPERIMENTAL
Intervention: Ongoing randomized preventive trials
Number of subjects: 0
Study: 8653531

Group type: EXPERIMENTAL
Intervention: 200 mg/d of sertraline
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 53
Study: 2231066

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study: 344125

Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 30007333

Group type: EXPERIMENTAL
Intervention: 0.018-inch slot bracket system
Number of subjects: 187

Group type: COMPARATOR
Intervention: 0.022-inch slot bracket system
Number of subjects: 187
Study: 28077114

Group type: EXPERIMENTAL
Intervention: the worksite cafeteria 2.0 intervention (12-week duration)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 26729950

Group type: EXPERIMENTAL
Intervention: Adjunct statin therapy with DMARDs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional DMARD therapy
Number of subjects: 60
Study: 24410484

Group type: EXPERIMENTAL
Intervention: Canrenone 25 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 120
Study: 21849651

Group type: EXPERIMENTAL
Intervention: RANTES
Number of subjects: 9771

Group type: EXPERIMENTAL
Intervention: IP-10
Number of subjects: 9771

Group type: EXPERIMENTAL
Intervention: eotaxin-1
Number of subjects: 9771

Group type: EXPERIMENTAL
Intervention: MCP-1
Number of subjects: 9771

Group type: EXPERIMENTAL
Intervention: RANTES and IP-10 (combined in multivariate model)
Number of subjects: 9771
Study: 19268890

Group type: EXPERIMENTAL
Intervention: 350 microg dexamethasone DDS
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 700 microg dexamethasone DDS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (both dosages)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (700 microg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dexamethasone DDS (350 microg)
Number of subjects: 41
Study: 17710010

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (n=17)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Topical lidocaine (n=18)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (healthy women, n=30)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients (combined treatment)
Number of subjects: 35
Study: 16162697

Group type: EXPERIMENTAL
Intervention: Lansoprazole, 30 mg bid for 24 weeks
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo, bid for 24 weeks
Number of subjects: 207
Study: 12212780

Group type: EXPERIMENTAL
Intervention: AMPAKINE CX516
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10455094

Group type: EXPERIMENTAL
Intervention: Mivazerol (oral administration over a two week period)
Number of subjects: 25
Study: 7608352

Group type: EXPERIMENTAL
Intervention: Retrospective mood ratings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prospective mood ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative emotional states
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative emotions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal determinants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrapersonal determinants
Number of subjects: 0
Study: 2611434

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 ml of 100% alcohol/kg body weight)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 59012

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis B vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-vaccinated subjects
Number of subjects: 0
Study: 30427588

Group type: EXPERIMENTAL
Intervention: Ertugliflozin monotherapy (15 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC (15-100 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Metformin FDC (7.5-1000 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ertugliflozin monotherapy and FDCs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ertugliflozin and ertugliflozin/Sitagliptin FDC
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Metformin FDC
Number of subjects: 14
Study: 28243359

Group type: EXPERIMENTAL
Intervention: 5% BPC‐350
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 6% BPC‐350
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 5% BPC‐350 (in Meal 2 and 3)
Number of subjects: 11
Study: 26431906

Group type: EXPERIMENTAL
Intervention: ARA290 (2 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 24267254

Group type: EXPERIMENTAL
Intervention: Triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mono-therapy with simvastatin (40 mg daily)
Number of subjects: 102
Study: 20727626

Group type: EXPERIMENTAL
Intervention: New fortifier (NF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard fortifier (SF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reformulated fortifier (RF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All infants studied with MA
Number of subjects: 30
Study: 19723123

Group type: EXPERIMENTAL
Intervention: Tonabersat, a gap-junction modulator, well tolerated, no cardiovascular effects, pharmacokinetic profile suggests usefulness in migraine prophylaxis.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiepileptic drugs and beta-blockers, commonly used preventive therapies, mechanisms of action unknown.
Number of subjects: 0
Study: 15217131

Group type: EXPERIMENTAL
Intervention: Rectal administration of 15 ml 2% Lidocaïne gel
Number of subjects: 308

Group type: COMPARATOR
Intervention: Lidocaïne periprostatic infiltration (10 ml of 1% Lidocaïne in two injections)
Number of subjects: 308
Study: 10602355

Group type: EXPERIMENTAL
Intervention: Low-fat wood stanol ester margarine (WSEM)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vegetable oil stanol ester margarine (VOSEM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no stanol esters) margarine
Number of subjects: 60
Study: 7863993

Group type: EXPERIMENTAL
Intervention: Atenolol (50 and 100 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1645332

Group type: EXPERIMENTAL
Intervention: BV-araU 150 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BV-araU 30 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both doses of BV-araU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BV-araU (both doses)
Number of subjects: 0
Study: 6789665

Group type: EXPERIMENTAL
Intervention: Single-solution regimen
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 31883251

Group type: EXPERIMENTAL
Intervention: Advanced Platelet-rich Fibrin (A-PRF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 10
Study: 27553058

Group type: EXPERIMENTAL
Intervention: Assigned weight label of 'overweight'
Number of subjects: 113
Study: 26618505

Group type: EXPERIMENTAL
Intervention: GSM 900 MHz exposure
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WCDMA/UMTS exposure
Number of subjects: 30
Study: 24918555

Group type: EXPERIMENTAL
Intervention: Isotretinoin-Lidose
Number of subjects: 925

Group type: COMPARATOR
Intervention: Food-dependent generic isotretinoin
Number of subjects: 925
Study: 22124576

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 160
Study: 19787809

Group type: EXPERIMENTAL
Intervention: Boceprevir (400 mg twice or three times daily for 14 days)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Mathematical modeling
Number of subjects: 22
Study: 17287062

Group type: EXPERIMENTAL
Intervention: Impact Model 730 automatic transport ventilator (Impact 730)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional bag valve mask (BVM) ventilation
Number of subjects: 28
Study: 15054653

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anesthesia (group B)
Number of subjects: 20
Study: 11575414

Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam with bupivacaine (BM1: 1 ml of 0.5% bupivacaine plus 0.2 ml of 0.5% midazolam)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam with bupivacaine (BM2: 1 ml of 0.5% bupivacaine plus 0.4 ml of 0.5% midazolam)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (1 ml of 0.5% heavy bupivacaine plus 0.2 ml of 0.9% saline)
Number of subjects: 45
Study: 9849260

Group type: EXPERIMENTAL
Intervention: Three noncontact Therapeutic Touch treatments (15 to 20 minutes duration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Three rest periods (Control group)
Number of subjects: 20
Study: 7927447

Group type: EXPERIMENTAL
Intervention: Hand sewn anastomosis (performed in two layers with 3/0 silk)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stapled anastomosis (using EEA staplers)
Number of subjects: 60
Study: 31782661

Group type: EXPERIMENTAL
Intervention: Usual care and person-centred care (PCC) in the form of structured telephone support, n=39
Number of subjects: 77

Group type: COMPARATOR
Intervention: Usual care, n=38
Number of subjects: 77
Study: 30214821

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prednisolone plus antibiotics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Expectant observation plus prednisolone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antibiotic alone
Number of subjects: 60
Study: 28708678

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 939

Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C or 36°C
Number of subjects: 939
Study: 26289950

Group type: EXPERIMENTAL
Intervention: Pharmacist-acquired medication history (MH) during admission to ED
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard care (no pharmacist-acquired MH)
Number of subjects: 270
Study: 23108436

Group type: EXPERIMENTAL
Intervention: Core instability strength training (CIT) for 9 weeks
Number of subjects: 32
Study: 21419314

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) diet (40% carbohydrate/15% mixed protein/15% whey protein/30% fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Whey protein (WP) diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control diet (CD) (55% carbohydrate/15% protein/30% fat)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mixed protein diet (40% carbohydrate/30% protein/30% fat)
Number of subjects: 18
Study: 19135415

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.75 mg) with dexamethasone (16 mg IV on day 1, followed by 8 mg IV for cisplatin or 4 mg orally for AC/EC on days 2 and 3)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Granisetron (40 microg/kg) with dexamethasone (16 mg IV on day 1, followed by 8 mg IV for cisplatin or 4 mg orally for AC/EC on days 2 and 3)
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Palonosetron (0.75 mg) with dexamethasone
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Granisetron (40 microg/kg) with dexamethasone
Number of subjects: 1143
Study: 17874980

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 80
Study: 14734594

Group type: EXPERIMENTAL
Intervention: Memantine (starting dose 5 mg/d, increased to 20 mg/d, n = 203)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo (n = 201)
Number of subjects: 404
Study: 12575607

Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI) 40 ml (equivalent to 80 g crude drug) in 5% glucose solution 500 ml for intravenous dripping, once a day for 2 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nitrolingual injection 15 mg in 5% glucose solution 500 ml for intravenous dripping, once a day for 2 weeks
Number of subjects: 83
Study: 9597024

Group type: EXPERIMENTAL
Intervention: Self-selected diet with a goal of 15% of energy from fat
Number of subjects: 21
Study: 8163713

Group type: EXPERIMENTAL
Intervention: Active drug with forced titration scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active drug (three arms with different maximum allowable doses)
Number of subjects: 0
Study: 2894789

Group type: EXPERIMENTAL
Intervention: Alcuronium 0.2 mg.kg‐1
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vecuronium 0.08 mg.kg‐1
Number of subjects: 28
Study: 31635538

Group type: EXPERIMENTAL
Intervention: Present-centered therapies for PTSD
Number of subjects: 141

Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 141
Study: 29808316

Group type: EXPERIMENTAL
Intervention: Bevacizumab/Irinotecan (BEV/IRI)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 142
Study: 27485267

Group type: EXPERIMENTAL
Intervention: Coaxial technique
Number of subjects: 240

Group type: COMPARATOR
Intervention: Noncoaxial technique
Number of subjects: 240
Study: 26062108

Group type: EXPERIMENTAL
Intervention: 0.5 mg E + 15 mg P (Group A)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1 mg E + 20 mg P (Group B)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 1 mg E + 30 mg P (Group C)
Number of subjects: 84
Study: 22961097

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 56
Study: 20353582

Group type: EXPERIMENTAL
Intervention: Paper-and-pencil at home via the mail
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Paper-and-pencil at the hospital clinic
Number of subjects: 314

Group type: COMPARATOR
Intervention: All modes of administration
Number of subjects: 314
Study: 18431266

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study: 16891634

Group type: EXPERIMENTAL
Intervention: 60 mg hyperbaric articaine hydrochloride (A60)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 84 mg hyperbaric articaine hydrochloride (A84)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 108 mg hyperbaric articaine hydrochloride (A108)
Number of subjects: 90
Study: 12805327

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (intravenous mitomycin 1.33 mg/m2, fluorouracil 166.7 mg/m2, cytarabine 13.3 mg/m2 twice weekly for 3 weeks, followed by oral fluorouracil 134 mg/m2 daily for 18 months, total dose 67 g/m2)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 252
Study: 10757249

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 17
Study: 8855834

Group type: COMPARATOR
Intervention: Placebo, no exercise
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), no exercise
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo, exercise
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TE plus exercise
Number of subjects: 43
Study: 1740582

Group type: EXPERIMENTAL
Intervention: Ragweed immunotherapy (IT)
Number of subjects: 53
Study: 6514487

Group type: EXPERIMENTAL
Intervention: Hypnosis with suggestion to overcome displacement aftereffects (hypothesis informed)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Slow motion movement during posttest
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group with no special instructions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hypothesis-informed group in Study 2
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group in Study 2
Number of subjects: 50
Study: 31575585

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (BOTOX) at 8 UI/kg in the internal shoulder rotator muscles
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham procedure mimicking BTI
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (BTI and Sham)
Number of subjects: 62
Study: 29705054

Group type: EXPERIMENTAL
Intervention: Oral steroid therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (nonsteroid group)
Number of subjects: 38
Study: 27742246

Group type: EXPERIMENTAL
Intervention: 42-mm glenosphere
Number of subjects: 81

Group type: COMPARATOR
Intervention: 38-mm glenosphere
Number of subjects: 81
Study: 25449826

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) therapy
Number of subjects: 29
Study: 22382037

Group type: EXPERIMENTAL
Intervention: Proactive strategy with periodic email prompts
Number of subjects: 9169

Group type: COMPARATOR
Intervention: Control group (no email prompts)
Number of subjects: 9169
Study: 20890791

Group type: EXPERIMENTAL
Intervention: Neodolpasse(®) Infusion Solution
Number of subjects: 120

Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 120
Study: 17557933

Group type: EXPERIMENTAL
Intervention: Intervention group (prenatal education and home-based postpartum support)
Number of subjects: 0
Study: 15084760

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg once a month for 3 months and cyproterone acetate 300 mg once a week for 3 weeks (group A)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (surgery without any pretreatment, group B)
Number of subjects: 167
Study: 11553182

Group type: EXPERIMENTAL
Intervention: Group 2 (offspring of two parents with Type 2 diabetes)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Group 1 (no family history of diabetes)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Minimum microvascular resistance
Number of subjects: 42
Study: 9757854

Group type: COMPARATOR
Intervention: Nafarelin alone (200 microg intranasally twice daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nafarelin plus human parathyroid hormone‐(1‐34) (hPTH‐[1‐34]) (40 microg subcutaneously daily)
Number of subjects: 43